30 closest matches · ranked by relevance
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Multiple Myeloma
Primary: International Myeloma Working Group (IMWG) Response Criteria — 8; 4; 7; 19 participants
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of Carfilzomib and Pegylated Liposomal Doxorubicin (Phase I - Part 1). — 56; 30 mg/m^2
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Progression-free Survival at 18 Months (PFS18) Defined as the Proportion of Patients Alive and Free From Disease Progression at 18 Months From Study Entry — 0.3750…
Multiple Myeloma
Primary: Part 2: Percentage of Participants With Overall Response Rate (ORR) Per International MyelomaWorking Group (IMWG) as Assessed by an Independent Review Committee (IRC)…
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Event-free Survival — 29 percentage of participants
Multiple Myeloma
Primary: Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage — 0; 0; 0; 0 Participants
Plasma Cell Leukemia · Plasmacytoma · Recurrent Plasma Cell Myeloma
Primary: Progression Free Survival (PFS) — 38; 24 Participants
Multiple Myeloma
Primary: Overall Response Rate (PR or Better) of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory MM Refractory to a Previous…
Recurrent Mantle Cell Lymphoma
Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants
Recurrent Plasma Cell Myeloma · Refractory Plasma Cell Myeloma
Primary: Proportion of Confirmed Tumor Responses Defined to be a Partial Response or Better Noted as the Objective Status on Two Consecutive Evaluations — .4; .25 proportion of…
Multiple Myeloma
Primary: Phase I: Number of Patients With Dose Limiting Toxicity — 0; 0; 0; 0 Participants
ISS Stage I Plasma Cell Myeloma · ISS Stage II Plasma Cell Myeloma · ISS Stage III Plasma Cell Myeloma
Primary: Number of Participants With Adverse Events — 8 Participants
Refractory Plasma Cell Myeloma
Primary: Overall Response Rate — 0.35 proportion of participants
Relapsed or Refractory Multiple Myeloma
Primary: Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC) — 57.7 percentage of participants
Multiple Myeloma
Primary: Overall Response Rate — 6; 1; 20; 43 Participants
Multiple Myeloma
Primary: Time to Progression of Disease — 12.6; 9.9 Months — p=0.196
Multiple Myeloma and Plasma Cell Neoplasm
Primary: The Number of Confirmed Hematologic Responses (Complete, Partial, or Very Good Partial Response) — 39; 11; 9; 10 participants
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 53; 14; 35 Participants
Multiple Myeloma
Primary: Number of Participants With Adverse Events (AEs) — 6 Participants
Refractory Multiple Myeloma
Primary: Find Maximum Tolerated Dose (MTD) of Bortezomib in Combination With Pomalidomide and Dexamethasone Out to 2.5 Years, by Count of Patients With Dose Limiting Toxicities…
Multiple Myeloma in Relapse · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Primary: Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bevacizumab and Lenalidomide — 64 percentage of participants
Myeloma
Primary: Participants Who Had Measurable Disease at Time of Transplant and Achieved a Stringent Complete Remission — 16 Participants
Multiple Myeloma
Primary: Phase 1: Participants With Dose-Limiting Toxicities (DLT) in Cycle 1 — 1; 1; 2; 4 participants
Multiple Myeloma · Plasma Cell Leukemia
Primary: Overall Survival (OS) — 40 months
Multiple Myeloma
Primary: Number of Participants With VGPR or Better Response to Induction — 6 Participants — p=0.597
Multiple Myeloma
Primary: Overall Response Rate (ORR) by Independent Review Committee (IRC) (Full Analysis Population) — 31; 34; 48 Percentage of Participants
Relapsed/Refractory Multiple Myeloma
Primary: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) — 2.6; 1.7 months — p==0.0054
Plasma Cell Leukemia · Plasma Cell Myeloma · Plasmacytoma
Primary: Confirmed Response Rate — 0.06 proportion of patients
Multiple Myeloma
Primary: Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants